Search clinical trials for: Decitabine

Total 3125 results

Chinese PLA General Hospital
Navy General Hospital, Beijing

Unknown

Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation

Recurrent Adult Acute Myeloid Leukemia

China
Mohammed Milhem
University of Iowa; Holden Comprehensive Cancer Center

Completed

Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Sarcoma | Pancreatic Ductal Adenocarcinoma

United States
Otsuka Beijing Research Institute

Recruiting

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

China
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Recruiting

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
Shandong University

Unknown

Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent

Myelodysplastic Syndromes

China
Astex Pharmaceuticals, Inc.

Completed

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States, Canada, Spain, Hungary, Austria, Czechia, France, Germany, Italy, United Kingdom
Chinese PLA General Hospital

Recruiting

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Hodgkin Lymphoma | Anti-PD-1 Antibody Resistant

China
M.D. Anderson Cancer Center

Recruiting

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Biphenotypic Leukemia | Refractory Acute Biphenotypic Leukemia

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University; Taiho Oncology, Inc.

Recruiting

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Genentech, Inc.; Astex Pharmaceuticals, Inc.

Recruiting

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States
Taiho Oncology, Inc.

Active, not recruiting

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Myelodysplastic Syndromes

Spain, United States, Belgium, Canada, Germany, Italy
Peking University

Unknown

Phase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors

Patients With Digestive System Tumors Resistant to PD-1 Inhibitors
ANRS, Emerging Infectious Diseases
INSERM SC10-US19

Recruiting

Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load (SYNACTHIV)

HIV-1-infection, Subtype b

Belgium, France
Eisai Inc.

Terminated

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Myelodysplastic Syndromes

United States
Astex Pharmaceuticals, Inc.

Completed

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome | MDS

United States, Canada
The First Hospital of Jilin University

Unknown

Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer (SLOWDOSE001)

Pancreatic Cancer
Taiho Oncology, Inc.

Enrolling by invitation

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States, Spain, Canada, Austria, Slovakia, Bulgaria, Hungary
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astex Pharmaceuticals, Inc.

Recruiting

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive | BCR-ABL1 Positive Chronic Myelogenous Leukemia | BCR-ABL1 Positive

United States
Astex Pharmaceuticals, Inc.

Terminated

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Xian-Janssen Pharmaceutical Ltd.

Completed

An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

China
Astex Pharmaceuticals, Inc.

Completed

Effect of Food on Blood Levels of ASTX727

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States
Mohammed M Milhem
Genentech, Inc.

Terminated

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (ML28604)

Melanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic Melanoma

United States
Janssen-Cilag Farmaceutica Ltda.
Janssen Korea, Ltd., Korea

No longer available

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Hong Kong, Brazil, Thailand
The First Affiliated Hospital of Soochow University

Unknown

Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation (DFMBHSCT)

Higher-risk Myelodysplastic Syndrome | Relapsed /Refractory Acute Myeloid Leukemia
Weill Medical College of Cornell University
Eisai Inc.

Completed

Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML

Acute Myeloid Leukemia

United States
European Organisation for Research and Treatment...

Unknown

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

Belgium, Netherlands, Germany, Italy, United Kingdom, Austria, Czech Republic, Croatia, Turkey, Switzerland
M.D. Anderson Cancer Center

Recruiting

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Taiho Oncology, Inc.

Active, not recruiting

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Spain, Canada
National Cancer Institute (NCI)

Completed

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

Esophageal Cancer | Lung Cancer | Metastatic Cancer | Malignant Mesothelioma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Decitabine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
The First Affiliated Hospital of Soochow University
Xian-Janssen Pharmaceutical Ltd.

Unknown

Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Myelodysplastic Syndromes | Acute Myelocytic Leukemia

China
California Cancer Consortium
National Cancer Institute (NCI)

Completed

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
National Cancer Institute (NCI)

Recruiting

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Mesothelioma | BRCA1-Associated Protein-1 (BAP1) Mutations | Malignant Mesothelioma (MM) | Early-stage Mesothelioma | Subclinical Mesothelioma | Early-stage BAP1-associated Malignancies

United States
Eisai Inc.

Completed

A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome

United States
Taiho Oncology, Inc.

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Spain, Poland, Bulgaria, Slovakia, Romania, Lithuania
The First Affiliated Hospital with Nanjing Medical...

Unknown

A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

China
Tianjin Medical University Cancer Institute and...

Recruiting

Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer | Decitabine | Adebrelimab (SHR-1316)

China
Eisai Inc.

Completed

Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Radboud University Medical Center

Completed

10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1

Acute Myeloid Leukemia (AML)

Netherlands, Belgium
Eisai Inc.

Terminated

A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Janssen Korea, Ltd., Korea

Completed

An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

Korea, Republic of
Wei Jiang
Guilin Hospital of Traditional Chinese Medicine

Unknown

Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
M.D. Anderson Cancer Center

Recruiting

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Bio-Path Holdings, Inc.

Recruiting

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Acute Myeloid Leukemia (AML)

United States
Taiho Oncology, Inc.

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Spain, Poland, Bulgaria, Slovakia, Romania, Lithuania
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia
Michael Savona
Incyte Corporation; Astex Pharmaceuticals, Inc.; Theradex

Recruiting

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) (ABNL-MARRO)

MDS/MPN

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial (PRECISE)

Lung Cancer | Non-small Cell Lung Cancer

United States
University of Florida
Hyundai Hope On Wheels

Completed

Phase I, Dose Escalation Study of Decitabine

Leukemia, Lymphoblastic, Acute | Leukemia, Myeloid Acute | Hematopoetic Myelodysplasia

United States

Search clinical trials for: Decitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations